Immunoglobulin A (IgA) nephropathy is a condition that causes a certain type of protein to build up in your kidneys. It progresses differently in everyone. Your kidneys might still work well years ...

The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...

Adults recently diagnosed with immunoglobulin A nephropathy who were assigned sparsentan as first-line therapy experienced rapid and sustained reductions in proteinuria, according to ...

Edgar Lerma, MD, provides insights into the pathophysiology of IgA nephropathy (IgAN) and the therapeutic promise of ...

IgA nephropathy (IgAN) is characterized by the deposition of IgA1-containing immune complexes in the glomerular mesangium. The pathogenesis follows a 4-hit cascade: ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...

The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...

Vera Therapeutics, Inc. (NASDAQ:VERA) said on Wednesday that it had completed full enrollment (431 participants) in the ...

Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...

Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...

Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...

APRIL is a cytokine that plays a key role in the pathogenesis of IgA nephropathy and we are optimistic about its potential to be an important treatment option for this progressive kidney disease.